REXAHN PHARMACEUTICALS, INC. Consulting Agreements
10 Contracts & Agreements
- Consulting Agreement, dated as of October 22, 2024, by and between the Company and Dr. Jean Bennett (Filed With SEC on November 12, 2024)
- Third Amendment to the Consulting Agreement, dated as of January 1, 2024, by and between the Company and Jay Pepose, M.D (Filed With SEC on May 10, 2024)
- Consulting Agreement between Ocuphire Pharma, Inc. and Jay Pepose, M.D., dated April 11, 2024 (Filed With SEC on April 17, 2024)
- Interim President and CEO Consulting Letter Agreement by and between Ocuphire Pharma, Inc. and Richard Rodgers, dated April 20, 2023 (Filed With SEC on May 15, 2023)
- Second Amendment to the Consulting Agreement dated December 1, 2022, by and between the Company and Jay Pepose (Filed With SEC on March 30, 2023)
- First Amendment to the Consulting Agreement dated September 19, 2022, by and between the Company and Jay Pepose (Filed With SEC on March 30, 2023)
- Consulting Agreement between the Registrant and Jay Pepose dated April 8, 2022 (Filed With SEC on May 13, 2022)
- Consulting Agreement, dated February 12, 2010, by and between the Company and JFS Investments (Filed With SEC on August 16, 2010)
- Consulting Agreement, dated as of August 12, 2008, between Rexahn Pharmaceuticals, Inc. and Y. Michele Kang (Filed With SEC on August 27, 2008)
- Registration Rights Agreement, dated as of December 24, 2007, by and among Rexahn Pharmaceuticals, Inc. and the purchasers pursuant to the KT&G Securities Purchase Agreement, the... (Filed With SEC on December 26, 2007)
